- Home >
- Clinicals Trials >
- DS1062-A-U303/ TROPION-Lung07
Lung cancer
DS1062-A-U303/ TROPION-Lung07
A Randomized Phase 3 Study of Datopotamab Deruxtecan;(Dato-DXd) and Pembrolizumab, with or Without Platinum;Chemotherapy, in Subjects with No Prior Therapy for;Advanced or Metastatic PD-L1 TPS <50% Non-squamous;Non-small Cell Lung Cancer Without Actionable Genomic;Alterations;(TROPION-Lung07)
- Open at Paris since : 08/10/2024
- Target : Adult
- Phase : Phase III
Trial description
To compare the efficacy of;Dato-DXd in combination;with pembrolizumab with or;without platinum-based;chemotherapy versus;pembrolizumab plus;pemetrexed and platinumbased;chemotherapy, as;measured by Progression-;Free Survival (PFS) by;blinded independent central;review (BICR).;To compare the efficacy of;Dato-DXd in combination;with pembrolizumab with or;without platinum-based;chemotherapy versus;pembrolizumab plus;pemetrexed and platinumbased;chemotherapy, as;measured by Overall;Survival (OS)
Url of the trialMain investigator
